The Ovarian Cancer Research Fund Inc
The Ovarian Cancer Research Fund Inc, operating as the Ovarian Cancer Research Alliance (OCRA), is a 501(c)(3) public charity located in New York, NY. Established in March 1995, the organization is classified as a grantmaking foundation and federated giving program dedicated to advancing research and support for ovarian and gynecologic cancers. The organization operates from 45 Rockefeller Plaza, 20th Floor, New York, NY 10111.
Financial Overview
From 2024 IRS Form 990-PF · View filing
Total Assets
$38.1M
-2.9% YoY
Annual Giving
$5.7M
-34.6% YoY
Grant Count
14
-22.2% YoY
Avg Grant Size
$405K
-15.9% YoY
Mission & Focus Areas
Ovarian Cancer Research Alliance is dedicated to curing ovarian cancer while improving treatments by advancing innovative science, promoting preventive measures, and advocating for, educating and supporting anyone affected by gynecologic cancers to ensure the best possible care and outcomes.
The organization's primary focus areas include:
- Research funding and scientific advancement
- Preventive measures and education
- Advocacy for patients and affected individuals
- Support programs for patients and loved ones
Grantmaking
OCRA is a significant funder of ovarian cancer research. Recent grant commitments include:
Ready to take the next step with The Ovarian Cancer Research Fund Inc?
Geographic Focus
Where this funder awards grants
The organization operates nationally, with support extending to patients and researchers across the United States. The organization has helped secure more than $3.7 billion in federal funding for research and education.
Grant Distribution by State
States
Cities
Financial History
Multi-year comparison from IRS filings
As of 2023:
- Total Assets: $39.2 million
- Total Revenue: $13.4 million
- Total Expenses: $13.8 million
- Total Liabilities: $14.7 million
As of 2022:
- Total Assets: $37.7 million
- Total Revenue: $16.4 million
- Employees: 29
The organization maintains a 100% Four-Star rating based on accountability, finance, leadership, and adaptability metrics.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Total Assets | $38,070,603 | $39,203,357 | $37,659,088 |
| Revenue | $10,047,998 | $13,442,515 | $16,425,940 |
| Expenses | $13,556,516 | $13,752,760 | $11,462,650 |
| Qualifying Distributions | — | — | — |
| Net Investment Income | $1,219,860 | $1,447,267 | $755,651 |
| Distributable Amount | — | — | — |
Giving Over Time
Total grant dollars and number of grants per year
Grant Insights
How this funder distributes its grants
Top Recipients
Top 10 recipients in 2024
Grant Size Distribution
85 grants across all recorded years
Open Grants
6 open opportunities from The Ovarian Cancer Research Fund Inc
AI Accelerator Grant
THE OVARIAN CANCER RESEARCH FUND INC
Amount
Varies
Deadline
Rolling / Open
Collaborative Research Development Grant
THE OVARIAN CANCER RESEARCH FUND INC
Amount
Up to US $900,000
Deadline
Rolling / Open
Collaborative Research Development Grant – Microsoft AI for Health
THE OVARIAN CANCER RESEARCH FUND INC
Amount
Up to US $900,000
Deadline
Rolling / Open
Giving History
Grant recipients and amounts by year
No grants recorded for .
Leadership & Key People
Leadership team and compensation from IRS filings
Audra Moran - President & CEO
Compensation Overview
From 2024 IRS filing
From 2024 filing
| Name | Title | Hours | Compensation |
|---|---|---|---|
| JOHN ORRICO | CHAIR | 3 | — |
| MATTHEW NEAL MILLER | VICE PRESIDENT | 2 | — |
| MARK TESSAR | TREASURER | 2 | — |
| ROBIN S COHEN | SECRETARY | 2 | — |
| DEBRA BIRNBAUM | DIRECTOR | 1 | — |
| THOMAS C LIEBMAN | DIRECTOR | 1 | — |
| JEANNETTE CHANG | DIRECTOR | 1 | — |
| DR CARMEL J COHEN | DIRECTOR | 1 | — |
| MEI-LI DA SILVA VINT ESQ | DIRECTOR | 1 | — |
| ANDREW FEUERSTEIN ESQ | DIRECTOR | 1 | — |
| CAROL J HAMILTON | DIRECTOR | 1 | — |
| JOHN W HANSBURY ESQ | DIRECTOR | 1 | — |
| CAROLINE HIRSCH | DIRECTOR | 1 | — |
| VERONICA JORDAN | DIRECTOR | 1 | — |
| DANA L MARK ESQ | DIRECTOR | 1 | — |
| CHRIS NEWCOMB | DIRECTOR | 1 | — |
| LISA SCHREIBER | DIRECTOR | 1 | — |
| ELLE SIMONE SCOTT | DIRECTOR | 1 | — |
| CHRISTOPHER TILBERIS | DIRECTOR | 1 | — |
| AUDRA L MORAN | PRESIDENT & CEO | 40 | $324,287 |
| JONATHAN ZEIDMAN | CHIEF DEVELOPMENT OFFICER | 40 | $189,019 |
| SARAH C DEFEO | CHIEF PROGRAM OFFICER | 40 | $166,391 |
| TRACY MOORE | VICE PRESIDENT, SUPPORT & EDUCATION | 40 | $157,837 |
| CHAD RAMSEY | VICE PRESIDENT, POLICY | 40 | $123,276 |
| NICOLE WARGO | VP - PHILANTHROPIC PARTNER | 40 | $126,274 |
| JESSICA HUGHSON ANDRADE | SENIOR DIRECTOR, STRATEGIC ALLIANCE | 40 | $108,675 |
| BRIAN PHAIR | DIRECTOR, DONOR RELATIONS | 40 | $102,012 |
Recent News & Activity
Recent developments and announcements
OCRA announced significant research investments in recent years:
2025 research funding of $10.8 million-plus with total commitment of $14.5 million
$10.8 Million-Plus For Research, $14.5 Million Total Commitment in 2025 |2024 grantees announced for Early Career Investigator Grants
Record $9.2 million investment in research initiatives for 2024
$10.8 Million-Plus For Research, $14.5 Million Total Commitment in 2025 |$7 million in research grants awarded for 2023
$10.8 Million-Plus For Research, $14.5 Million Total Commitment in 2025 |Subject Areas
Focus areas based on grantmaking activity
Data last updated April 2026. Sourced from IRS Form 990-PF filings. Research dossier generated April 2026.
What could you do with The Ovarian Cancer Research Fund Inc on Grantable?
- Assess strategic fit with your organization
- Draft a tailored letter of inquiry
- Find open RFPs from this funder
- Monitor for new funding opportunities